微创医学

目的探讨诱导排卵药物氯米芬（CC）、尿促性素（HMG）和绒促性素（HCG）治疗多囊性卵巢综合征（PCOS）伴不孕患者的临床疗效。方法选取43例患有多囊卵巢综合征而不孕的患者，根据使用促排卵药物组合的不同，分为CC/HCG、CC/HMG/HCG和HMG/HCG组。通过经阴道B超（TVS）测定并比较三组患者的HCG日子宫内膜厚度、多卵泡发生率、卵巢过度刺激综合征（OHSS）发病率、妊娠率和流产率。结果CC/HMG/HCG、HMG/HCG组HCG日平均子宫内膜厚度、多卵泡发生率和OHSS发生率明显高于CC/HCG组，差异具有统计学意义（P＜0.05）；CC/HMG/HCG与HMG/HCG组之间差异无统计学意义。3组之间妊娠率、流产率无统计学意义（P＞0.05）。结论对PCOS不孕患者使用任意一种促排卵方案都是可行的。但对于CC抵抗的患者，则建议使用CC/HMG/HCG或者HMG/HCG促排卵治疗。

ObjectiveTo investigate the clinical therapeutic effects of ovulation induction drugs like clomiphene citrate (CC), human menopausal gonadotropin (HMG), and human chorionic gonadotrophin (HCG) in patients with polycystic ovarian syndrome (PCOS). MethodsAccording to the different combinations of ovulation induction drugs, 43 patients with PCOS were divided into CC/HCG, CC/HMG/HCG, or HMG/HCG group. Endometrial thickness of HCG day, incidence of multiple follicular number, incidence of ovarian hyperstimulation syndrome (OHSS), pregnancy rate, and abortion rate of 3 groups were measured under B-ultrasound supervising and compared. ResultsEndometrial thickness of HCG day, incidence of multiple follicular number, incidence of ovarian hyperstimulation syndrome (OHSS) in CC/HMG/HCG and HMG/HCG groups were significantly higher than those in CC/HCG group, but no statistical difference was detected between CC/HMG/HCG and HMG/HCG groups (P＞0.05). There was no significant difference in pregnancy rate and abortion rate between 3 groups. ConclusionAll three ovulation induction strategies are feasible for infertility patients of PCOS. But for patients with CC resistance, the regimen of CC/HMG/HCG or HMG/HCG was recommended.